MK-4082 / Jiangsu Hansoh Pharma, Merck (MSD) - LARVOL DELTA

A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002) (clinicaltrials.gov) - P1 | N=120 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC

New P1 trial • Obesity

Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist (Businesswire) - "Merck...today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist...Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales."

Licensing / partnership • Metabolic Disorders